Table 3. Reports of prospective trials of combined modality therapy for locally advanced thymoma.
| Treatment | Stage | Patientsa | ORR | 5-yr OS |
|---|---|---|---|---|
| PAC, R (Loehrer et al, 1997) | III | 23 | 70% | 52.5%b |
| PAC, S, R (Kim et al, 2004) | III/IV | 22 | 77% | 95%c |
| CODE, S, R (current study) | III | 21 | 62% | 85%d |
Abbreviations: CODE=combination chemotherapy with cisplatin/vincristine/doxorubicin/etoposide; ORR: overall response rate; PAC=combination chemotherapy with cisplatin/doxorubicin/cyclophosphamide; R=thoracic radiotherapy; S=surgical resection; 5-yr OS=overall survival rate at 5 years.
a
Number of assessable patients.
b
Including patients with thymic carcinoma.
c
7-year OS rate was 79%.
d
8-year OS rate was 69%.